{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-024176","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.394660+00:00","generated_at":"2026-06-13T10:02:25.694625+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pulmatrix submits IND for PUR3100 Phase 2 trial in acute migraine","bullets":["IND submitted to FDA for PUR3100, an inhaled dry powder DHE formulation for acute migraine.","Phase 1 data showed PK similar to IV DHE with fewer side effects.","Phase 2 protocol investigates safety and preliminary efficacy in migraine patients.","Approximately 40 million U.S. patients with acute migraine need additional options.","PUR3100 uses proprietary iSPERSE dry powder delivery technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-024176","json":"https://secwatch.observer/filing/0001493152-23-024176.json","markdown":"https://secwatch.observer/filing/0001493152-23-024176.md","text":"https://secwatch.observer/filing/0001493152-23-024176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223024176/0001493152-23-024176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223024176/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:02:25.694625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}